This proposal seeks funding for the systemic build-up and testing of retroviral vectors, which transduce anti-HIV-1 therapeutic genes into human hematopoietic cells relevant in vivo gene therapy of HIV-1 infection. In the past years, our laboratories have made significant progress in the development of two important areas in gene therapy for HIV-1 infection: (1) Dr. Pomerantz's lab has developed a series of anti- HIV-1 single chain antibodies, which significantly inhibit HIV-1 replication at early stages of the retroviral life cycle. (2) Dr. Dornburg's laboratory has developed retroviral vectors, which display single chain antibodies (scAs) or other ligands on the viral surface of spleen necrosis virus, SV. Such vectors enabled an efficient (up to 10/6 cfu/ml), cell-type- specific gene transfer into various human hematopoietic cells. Cell-type- specificity was mediated by the scA. Now, experiments will be performed to combined these two technologies to establish potent anti-HIV-1 therapeutic gene transfer systems for in vivo gene therapy for HIV-1 infection. (1) Recently, three different SNV-derived packaging systems have been developed to transduce gene specifically into various human T- cells or CD34-positive hematopoietic stem cells with efficiencies above 10/6 cfu/ml. Using these systems, vectors will be developed and systematically improved to transduce anti-HIV-1 therapeutic genes developed and tested in Dr. Pomerantz's laboratory into human T-cells. The efficiency of the gene transfer and the level of protection against HIV-1 will be determined and compared to other vector systems. (2) Cell- type specificity and the efficiency of infection of all targeting vectors will be tested in SCID mice model systems. E.G., human target and non-target cells will be implanted into SCID mice, followed by the injection of retroviral vector preparations, specific for one cell type. First, human cells as well as various mouse tissues will be investigated for the presence of marker genes transduced by the targeting vector particles. Next, the experiments will be expanded to test the therapeutic effect of anti-HIV-1 genes in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI046149-01A1
Application #
6078547
Study Section
Special Emphasis Panel (ZRG1-AARR-3 (01))
Program Officer
Bridges, Sandra H
Project Start
2000-02-15
Project End
2004-01-31
Budget Start
2000-02-15
Budget End
2001-01-31
Support Year
1
Fiscal Year
2000
Total Cost
$243,219
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Cheng, Xiandong; Mukhtar, Muhammad; Acheampong, Edward A et al. (2007) HIV-1 Vpr potently induces programmed cell death in the CNS in vivo. DNA Cell Biol 26:116-31
Acheampong, Edward A; Parveen, Zahida; Muthoga, Lois W et al. (2005) Human Immunodeficiency virus type 1 Nef potently induces apoptosis in primary human brain microvascular endothelial cells via the activation of caspases. J Virol 79:4257-69
Chen, Wei; Tang, Zhonghua; Fortina, Paolo et al. (2005) Ethanol potentiates HIV-1 gp120-induced apoptosis in human neurons via both the death receptor and NMDA receptor pathways. Virology 334:59-73
Marusich, Elena I; Parveen, Zahida; Strayer, David et al. (2005) Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection. Virology 332:258-71
Parveen, Zahida; Mukhtar, Muhammad; Goodrich, Adrienne et al. (2004) Cross-packaging of human immunodeficiency virus type 1 vector RNA by spleen necrosis virus proteins: construction of a new generation of spleen necrosis virus-derived retroviral vectors. J Virol 78:6480-8
Argyris, Elias G; Kulkosky, Joseph; Meyer, Marie E et al. (2004) The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity. Virology 330:481-6
Dornburg, Ralph (2003) The history and principles of retroviral vectors. Front Biosci 8:d818-35
Dornburg, Ralph (2003) Reticuloendotheliosis viruses and derived vectors for human gene therapy. Front Biosci 8:d801-17
Krupetsky, Anna; Parveen, Zahida; Marusich, Elena et al. (2003) Retroviral packaging cells encapsulated in TheraCyte immunoisolation devices enable long-term in vivo gene delivery. Front Biosci 8:a94-101
Parveen, Zahida; Mukhtar, Muhammad; Rafi, Mohammed et al. (2003) Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. Virology 314:74-83